One proposed mechanism for reduced natriuretic peptide concentrations in obesity is the relative abundance of natriuretic peptide clearance receptors (NPR‐C) in adipose tissue.13, 22 Elevated insulin has also been linked to increased expression of NPR‐C in obese subjects.23 On the other hand, plasma Nt‐proANP and Nt‐proBNP levels are reduced in obesity to a comparable degree as the mature peptides. Because the pro‐peptides are not known to bind to NPR‐C, impaired synthesis or secretion likely plays a role in obesity.
These results also demonstrate that, unlike hGH, AOD9604 has no negative effect on carbohydrate metabolism. This was previously demonstrated in mice. Chronic administration of hGH to ob/ob mice depressed glucose oxidation and increase plasma glucose levels. AOD9604 had no such effects, no changes in circulating plasma glucose in either lean nor obese ob/ob mice have been observed [20]. AOD9604 did not cause hyperglycemia or affect insulin sensitivity in rats and mice [18, 20].
The test substance was either administered intravenously (studies METAOD001 and METAOD002) or as a capsule/tablet. The hexadecapeptide AOD9604 was produced under cGMP conditions by PolyPeptide Laboratories (Torrance, CA, USA). For studies 1 and 2, the product was supplied in a lyophilized form and reconstituted before usage with the designated volume of sterile water for intravenous injection. The capsules/tablets were manufactured using a common excipient mix (Capsules: Mannitol, PEG3350 (in studies METAOD003, METAOD004 and METAOD005)); or Tablets: L-Arginine Free Base, Microcrystalline Cellulose, Fumed silica, Magnesium Stearate (in study METAOD006)).
Due to the similarity of AOD9604 to the C-terminus component of hGH some parameters that are associated with hGH activity have been carefully monitored in the long-term studies: 1). Oral glucose tolerance tests (OGTT) were conducted to assess the effect of treatment on glucose handling. 2). Testing for any anti-AOD9604 antibodies in blood samples of participants was conducted to investigate if oral administration of AOD9604 resulted in the generation of neutralizing antibodies. 3). Serum levels of IGF-1 were measured to confirm the hypothesis that unlike hGH, AOD9604 does not act via IGF-1 or raise IGF-1 levels.

Very tough to say. I am not a doctor and this is not to be taken, interpreted or construed as medical advice. Please talk with a licensed medical professional about this. These are just my own personal thoughts and not a prescription or a diagnosis or any form of health care whatsoever. I could possibly help but would need to see your health history, blood, biomarkers, etc. I'd be happy to help you via a personal one-on-one consult. Just go to https://bengreenfieldfitness.com/coaching. and then choose a 20 or 60 minute consult, whichever you'd prefer. I can schedule ASAP after you get that.
If there was a magic pill that could help improve digestion and gut health, erase wrinkles, ease joint pain and give you healthy, thick hair and nails, I would buy it by the truckload. After all, while boosting my overall health is a priority, having shinier hair and minimal crow’s feet is a major bonus. Although there’s no such magic pill, there is a supplement that promises these results and more—collagen peptides.
There are different things you have to consider when wanting to purchase peptides on the web. In the event that you would prefer not to squander your time and cash and hazard your life to get low quality peptides, dependably settle with the most solid and legitimate peptide provider as this can have a gigantic effect. In the event that despite everything you can’t locate a decent provider of first rate quality peptides, you can request your other’s proposals. You may likewise look at PEPTIDE CLINICS in the event that you need.
These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.
IGF-1 also increases the activity of muscle protein synthesis and the activity of muscle stem cells (also called satellite cells) for repair of damaged muscle. This is probably why intense weight training is one primary stimulus for a natural release of IGF-1 in muscle. As a matter of fact, exercise researchers have found that systemic IGF-1 normally produced in the liver isn’t even required for this type of muscle repair, as other IGF-1 forms produced by your own muscles during and post-exercise allows for adequate muscle tissue repair.
This peptide is a modified fragment of hGH which contains the portion of the molecule that is believed to be responsible for hGH’s anti-obesity effects. The peptide has been shown to increase fat burning without the increase in blood sugar and growth rate that has been seen with hGH itself. AOD 9604 has been deemed safe for chronic use by the FDA, receiving Human GRAS status in 2014. In addition to its utility as an anti-obesity peptide, AOD 9604 has been shown to have very favorable cartilage repair and regenerative properties, especially when paired with peptide BPC 157.

“We are delighted with these results,” stated Metabolic Pharmaceuticals CEO, Chris Belyea. “The evidence from the trial is that over 12 weeks AOD9604 induces competitive weight loss with accompanying health benefits at a low dose and has superior tolerability. Our next major focus is a partnership with a major pharmaceutical company to assist in financing late stage longer term human clinical trials for worldwide marketing approval as a prescription treatment.”
Our Privacy Policy includes important information about our collection, use and disclosure of your personal information (including to provide you with targeted advertising based on your online activities). It explains that if you do not provide us with information we have requested from you, we may not be able to provide you with the goods and services you require. It also explains how you can access or seek correction of your personal information, how you can complain about a breach of the Australian Privacy Principles and how we will deal with a complaint of that nature.
The objective of the 3rd study (METAOD003) was to assess the safety, tolerability and pharmacodynamics of single oral doses of AOD9604 in healthy, clinically obese males. 17 subjects (n = 15 completed the study), age 35 to 54 years, with a BMI ≥ 35 kg/m2 (range 35 to 56 kg/m2) subsequently received 3 increasing doses of AOD9604 (9, 27 and 54 mg) or placebo. Each dose administration was separated by a 2-week wash-out period.

Cancer can often be a process of uncontrolled cellular division. IGF-1 is not only pro-growth in a way that could increase this cellular division, but IGF-1 also inhibits apoptosis, or programmed cell death. Hence the theory among some in the medical community that tumors could increase synthesis of IGF-1 to keep themselves alive and to encourage the spread of cancer throughout the body. This doesn’t mean that IGF-1 directly causes cancer.


As women age, the #1 reason for weight gain is hormonal imbalance. In fact, hormonal imbalance can lead to unwanted adult acne, loss of sexual desire, and sagging breasts. When you correct this imbalance, you begin to lose body fat, overcome acne, naturally lift and enhance breast tissue, and improve libido! OxySelect Pink was formulated for women by women, and the results are incredible and comes with a 100% money-back guarantee! Read More
Echocardiograms were performed before and after saline infusion at both the baseline and post‐gastric bypass surgery visits. Each subject had four echocardiograms in total during the entire study. Interpretations were made by investigators blinded to clinical status (before or after saline infusion, before or after surgery). The following standard measures were made on two‐dimensional (2D) images in each echocardiogram: interventricular septal and posterior wall thickness (IVS and PWT), left ventricular internal diameter at end‐diastole and end‐systole (LVID, LVIS) and left atrial anteroposterior diameter (LA Dia) in the parasternal view, left ventricular (LV) volumes using a modified Simpson's rule (apical 4 chamber and 2 chamber views), mitral inflow E and A velocities and E deceleration time, and mitral annular early diastolic (e′) velocity at the lateral annulus. We did not calculate left atrial volumes due to limited echocardiographic windows in severely obese patients. Estimation of left atrial filling pressure was obtained every 20 minutes during the second hour of the infusion by determining the ratio of the early diastolic mitral inflow velocity to the early diastolic mitral annular velocity.15
Human Growth Hormone (hGH) is not only important for growth processes during childhood, but plays a pivotal role in lipid metabolism throughout life. It is well known that hGH is involved in the regulation of lipolysis and lipogenesis. Therefore, hGH was implicated as a good potential candidate for the treatment of obesity. However undesired side effects, such as induction of glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13] rendered therapeutic doses of hGH unsuitable for long-term treatments in humans.

Prolonged use of intact hGH may result in negative effects on glucose metabolism, such as glucose intolerance and insulin resistance. Given that AOD9604 is a peptide fragment of the C-terminus of hGH, its effect on glucose control was monitored. OGTT testing was carried out on all patients during the screening phase as well as at various time points during the treatment period. No significant changes or obvious trends in the OGTT in any treatment group were observed, suggesting that AOD9604 supplementation does not deteriorate glucose control or induce insulin resistance. In contrast, treatment with AOD9604 seemed to have a positive effect in subjects with impaired glucose tolerance. In the 12 weeks treatment study, patients with impaired glucose tolerance supplemented with AOD9604 were less likely to develop diabetes during the study than subjects taking placebo. This hypothesis, however, has to be confirmed in a separate clinical trial. In contrast, in a recent clinical trial of hGH effects in obese women, hGH caused an increase in IGF-1 levels over a 6 month dosing period and decreased glucose tolerance in a subset of trial participants [29].
“We are delighted with these results,” stated Metabolic Pharmaceuticals CEO, Chris Belyea. “The evidence from the trial is that over 12 weeks AOD9604 induces competitive weight loss with accompanying health benefits at a low dose and has superior tolerability. Our next major focus is a partnership with a major pharmaceutical company to assist in financing late stage longer term human clinical trials for worldwide marketing approval as a prescription treatment.”
Obese individuals have been found to have lower natriuretic peptide levels in multiple previous studies.12, 13, 14 The finding of lower natriuretic peptides in obese subjects is unexpected because obesity promotes increased plasma volume and hypertension, which are known to lead to left ventricular stress and hypertrophy. These conditions should trigger natriuretic peptide release from the heart. Thus, it has been proposed that obese individuals may have a primary “natriuretic peptide deficiency”8, 13 that could contribute to the development of hypertension.
Studies have shown that individuals fighting infection have a lower amount of circulating T α 1 and suppressed helper T cell numbers compared to healthy individuals. This is problematic, as optimal immune function is vital to recovery from infection. Supplementation with T α 1 has the potential for great therapeutic benefit for patients suffering from infection or autoimmune disease.
EPO: Erythropoietin (EPO) is a naturally occurring hormone found in the blood, but media usually refer to the artificial peptide (recombinant EPO). EPO stimulates production of red blood cells to improve oxygen transfer and boost endurance or recovery from anaerobic exercise. EPO is also believed to increase the risk of adverse health effects, but this has mainly been based on athletes’ anecdotal evidence and clinical studies in non-sports patients with other medical conditions. While using recombinant EPO is prohibited both in and out of competition under WADA’s Prohibited List, “natural” boosting of EPO through high altitude training is allowed.
As in the previous study there were no clinically relevant changes observed in safety laboratory parameters 24 hours following administration of AOD9604 or placebo. Similarly, there were no clinically relevant changes in vital signs (blood pressure, radial pulse rate and temperature) or ECGs recorded at any of the scheduled time points up to 24 hours post dose. There were no significant changes in glucose or IGF-1 levels following AOD9604 treatment compared with placebo.
For example, if 100mcg more were to be administered after the first 100mcg (making the effective dose of 200mcg), then the second dose will achieve only 50% of what the first dose already did. A 100mcg more (making a total of 300mcg) will achieve only 25% more of the initial dose. This implies that, in order to increase the effect of the compound, only a little more of it can be successfully administered after the saturation dose.

The process to get a cream doesn't happen overnight. Explains Smeath: "A patient will complete a comprehensive medical questionnaire, which is sent to one of our prescribing doctors. [They] review all medical notes, make contact with the patient and once approved, send a prescription to one of two TGA-approved compounding pharmacies in Australia who ship [the peptides] directly."
×